ストックスクリーナーアプリを入手
13.94
0.50%
0.07
前日終値:
$13.87
開ける：
$13.82
24時間の取引高:
891.14K
Relative Volume:
0.88
時価総額：
$11.64B
収益：
$3.85B
当期純損益:
$667.93M
株価収益率:
21.22
EPS:
0.657
ネットキャッシュフロー:
$142.30M
1週間 パフォーマンス:
+3.57%
1か月 パフォーマンス:
-0.21%
6か月 パフォーマンス:
-1.41%
1年 パフォーマンス:
-2.11%
1日の値動き範囲:
$13.82
$13.98
1週間の範囲:
$13.44
$14.02
52週間の値動き範囲:
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
RDY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.94 | 11.55B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-12-19 | ダウングレード | Nomura | Buy → Neutral |
| 2024-01-11 | ダウングレード | Jefferies | Buy → Underperform |
| 2023-08-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-05-18 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-30 | 開始されました | JP Morgan | Underweight |
| 2022-11-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 再開されました | BofA Securities | Neutral |
| 2021-07-27 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-09-18 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-09-18 | アップグレード | Investec | Sell → Hold |
| 2020-01-28 | ダウングレード | CLSA | Buy → Outperform |
| 2020-01-27 | ダウングレード | CLSA | Buy → Outperform |
| 2020-01-09 | アップグレード | Citigroup | Sell → Buy |
| 2019-11-04 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | アップグレード | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | アップグレード | Macquarie | Neutral → Outperform |
| 2019-06-20 | 開始されました | Deutsche Bank | Hold |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-20 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | アップグレード | CLSA | Outperform → Buy |
| 2019-01-17 | ダウングレード | Citigroup | Neutral → Sell |
| 2017-09-21 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | アップグレード | CLSA | Underperform → Outperform |
| 2017-07-28 | ダウングレード | CLSA | Underperform → Sell |
| 2016-07-27 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2016-07-27 | ダウングレード | Jefferies | Hold → Underperform |
| 2016-02-10 | アップグレード | Credit Agricole | Underperform → Buy |
| 2015-11-10 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Dr Reddys Laboratories Ltd Adr (RDY) 最新ニュース
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Fintech ADRs Dropped While Telecoms And Pharma Firmed Up - Finimize
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
L&T, Dr Reddys Labs, Coal India, Varun Beverages — Check Price Target Changes From Analysts - NDTV Profit
Why Dr Reddy’s stock may fall today; buzzing stocks list - BusinessLine
Indian pharma giant says Health Canada rejected its application to make generic semaglutide - The Globe and Mail
Asian ADRs See Mixed Results With Fintech In Focus - Finimize
Dr Reddys ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - NDTV Profit
Asian Stocks See Gains In US Trading This Week - Finimize
Dr. Reddy’s Labs ADR earnings beat, revenue topped estimates By Investing.com - Investing.com Nigeria
Dr. Reddy’s Labs ADR earnings beat, revenue topped estimates - Investing.com
Dr. Reddy's Earnings: Solid Growth Seen, Despite Softness in US, Thanks to Growing European Presence - Morningstar
Asian ADRs Kept Steady As Investors Pick Favorites - Finimize
Asian Stocks Climb In The US As Big Names Rally - Finimize
Infosys Q2 results out! Here’s what experts, Infosys ADR signal about stock price - Mint
Asian ADRs Stay Calm As Individual Stocks Swing Both Ways - Finimize
Dr. Reddy's Laboratories Ltd Common Stock (NY: - FinancialContent
Asian Stocks In The US Closed Lower This Week - Finimize
Full Truck Alliance Co. Ltd. Sponsored ADR $YMM Shares Purchased by Mirae Asset Global Investments Co. Ltd. - Defense World
Corporacion Inmobiliaria Vesta, S.A.B. de C.V. Sponsored ADR (NYSE:VTMX) Receives $31.33 Consensus Target Price from Analysts - Defense World
Cash per share of Dr. Reddy's Laboratories Ltd. Sponsored ADR – NYSE:RDY - TradingView
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
HB Wealth Management LLC Takes $181,000 Position in Dr. Reddy’s Laboratories Ltd $RDY - Defense World
Robeco Institutional Asset Management B.V. Buys 1,452,192 Shares of Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asian ADRs Rise As Regional Firms Show Mixed Performance - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr Reddys Share Price Update: Company Reports Negative Monthly Returns - Meyka
Dr. Reddy's Laboratories Ltd $RDY Shares Bought by Ballentine Partners LLC - MarketBeat
Dr Reddys Laboratories Ltd Adr (RDY) 財務データ
収益
当期純利益
現金流量
EPS
1.74%
0.48%
大文字化:
|
ボリューム (24 時間):